2 x ULN, then, observe for 3-6 months and
treat if no spontaneous HBeAg loss. Consider liver biopsy prior
to treatment if compensated. Immediate treatment if icteric or clinical decompensation. IFNa/pegIFNa, LAM, ADV, ETV, TDF or LdT may be used as initial therapy. ADV not preferred due to weak antiviral activity and high rate of resistance after 1st year. LAM and LdT not preferred due to high rate of drug resistance. End-point of treatment – Seroconversion from HBeAg to anti-HBe.